TRDA on Nasdaq
Entrada Therapeutics, Inc.
American pharmaceutical preparations company, incorporated in Delaware.
Price unavailable
Last updated Oct 18, 2026.
Overview
Compare with Celularity Inc, ALUMIS INC. or Cue Biopharma, Inc., or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-621.1%Operating margin3
-565.5%Net margin3
-87.9%Revenue growth, 20253
-47.0%Return on equity3
-$129.6MFree cash flow3
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Research and development99¢$142.3M
- Income tax1¢$924.0K
Out of $25.4M in revenue.3 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Collaboration revenue | $25.4M | $210.8M |
| Research and development | $142.3M | $125.3M |
| General and administrative | $41.0M | $38.5M |
| Total operating expenses | $183.3M | $163.8M |
| (Loss) income from operations | -$157.9M | $47.0M |
| Interest and other income | $15.1M | $19.5M |
| Total other income | $15.1M | $19.5M |
| (Loss) income before provision for income taxes | -$142.8M | $66.5M |
| Total income tax provision | $924.0K | $859.0K |
| Net (loss) income | -$143.8M | $65.6M |
| Net (loss) income per share, basic (in dollars per share) | -$3.47 | $1.76 |
| Net (loss) income per share, diluted (in dollars per share) | -$3.47 | $1.68 |
| Weighted-average common shares outstanding, basic (in shares) | 41.4M shares | 37.3M shares |
| Weighted-average common shares outstanding, diluted (in shares) | 41.4M shares | 39.0M shares |
| Unrealized gain (loss) on marketable securities, net of tax of $0 | $695.0K | -$238.0K |
| Total other comprehensive income (loss) | $695.0K | -$238.0K |
| Total comprehensive (loss) income | -$143.1M | $65.4M |
| Unrealized (loss) gain on marketable securities, tax | $0 | $0 |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $90.4M | $101.2M | |
| Marketable securities | $205.3M | $318.8M | |
| Restricted cash, current portion | $658.0K | $0 | |
| Collaboration receivable | $1.2M | $3.7M | |
| Prepaid expenses and other current assets | $8.7M | $16.4M | |
| Total current assets | $306.3M | $440.0M | |
| Property and equipment, net | $7.3M | $10.9M | |
| Restricted cash, net of current portion | $3.3M | $4.0M | |
| Right-of-use assets, operating leases | $60.5M | $71.1M | |
| Other non-current assets | $70.0K | $284.0K | |
| Total assets | $377.4M | $526.3M | |
| Accounts payable | $2.3M | $4.3M | |
| Accrued expenses and other current liabilities | $17.7M | $13.3M | |
| Income taxes payable | $0 | $667.0K | |
| Operating lease obligations, current portion | $4.1M | $7.6M | |
| Deferred revenue, current portion | $342.0K | $13.7M | |
| Total current liabilities | $24.5M | $39.5M | |
| Operating lease obligations, net of current portion | $46.8M | $51.6M | |
| Deferred revenue, net of current portion | $0 | $6.5M | |
| Total liabilities | $71.2M | $97.6M | |
| Common stock, par value $0.0001; 150,000,000 shares authorized; 38,284,221 shares issued and outstanding as of December 31, 2025 and 37,585,944 shares issued and 37,574,538 shares outstanding as of December 31, 2024 | $4.0K | $4.0K | |
| Additional paid-in capital | $578.6M | $558.1M | |
| Accumulated other comprehensive income (loss) | $652.0K | -$43.0K | |
| Accumulated deficit | -$273.1M | -$129.3M | |
| Total stockholders equity | $306.1M | $428.7M | $242.4M |
| Total liabilities and stockholders equity | $377.4M | $526.3M | |
| Common stock, par value per share (in dollars per share) | $0.00 | $0.00 | |
| Common stock, shares, authorized (in shares) | 150.0M shares | 150.0M shares | |
| Common stock, shares, issued (in shares) | 38.3M shares | 37.6M shares | |
| Common stock, shares, outstanding (in shares) | 38.3M shares | 37.6M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $90.4M | $101.2M | |
| Marketable securities | $205.3M | $318.8M | |
| Restricted cash, current portion | $658.0K | $0 | |
| Collaboration receivable | $1.2M | $3.7M | |
| Prepaid expenses and other current assets | $8.7M | $16.4M | |
| Total current assets | $306.3M | $440.0M | |
| Property and equipment, net | $7.3M | $10.9M | |
| Restricted cash, net of current portion | $3.3M | $4.0M | |
| Right-of-use assets, operating leases | $60.5M | $71.1M | |
| Other non-current assets | $70.0K | $284.0K | |
| Total assets | $377.4M | $526.3M | |
| Accounts payable | $2.3M | $4.3M | |
| Accrued expenses and other current liabilities | $17.7M | $13.3M | |
| Income taxes payable | $0 | $667.0K | |
| Operating lease obligations, current portion | $4.1M | $7.6M | |
| Deferred revenue, current portion | $342.0K | $13.7M | |
| Total current liabilities | $24.5M | $39.5M | |
| Operating lease obligations, net of current portion | $46.8M | $51.6M | |
| Deferred revenue, net of current portion | $0 | $6.5M | |
| Total liabilities | $71.2M | $97.6M | |
| Common stock, par value $0.0001; 150,000,000 shares authorized; 38,284,221 shares issued and outstanding as of December 31, 2025 and 37,585,944 shares issued and 37,574,538 shares outstanding as of December 31, 2024 | $4.0K | $4.0K | |
| Additional paid-in capital | $578.6M | $558.1M | |
| Accumulated other comprehensive income (loss) | $652.0K | -$43.0K | |
| Accumulated deficit | -$273.1M | -$129.3M | |
| Total stockholders equity | $306.1M | $428.7M | $242.4M |
| Total liabilities and stockholders equity | $377.4M | $526.3M | |
| Common stock, par value per share (in dollars per share) | $0.00 | $0.00 | |
| Common stock, shares, authorized (in shares) | 150.0M shares | 150.0M shares | |
| Common stock, shares, issued (in shares) | 38.3M shares | 37.6M shares | |
| Common stock, shares, outstanding (in shares) | 38.3M shares | 37.6M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net (Loss) income | -$143.8M | $65.6M |
| Depreciation expense | $4.1M | $3.8M |
| Stock-based compensation expense | $19.6M | $17.9M |
| Net amortization of premium (accretion of discount) on marketable securities | -$3.7M | -$10.0M |
| Collaboration receivable | $2.5M | $2.2M |
| Prepaid expenses and other current assets | $7.6M | -$4.4M |
| Right-of-use assets, operating leases | $10.7M | $10.4M |
| Other non-current assets | $214.0K | $2.5M |
| Accounts payable | -$1.8M | $991.0K |
| Accrued expenses and other current liabilities | $4.7M | $1.7M |
| Income taxes payable | -$667.0K | -$3.4M |
| Deferred revenue | -$19.8M | -$119.8M |
| Operating lease liabilities | -$8.3M | -$9.0M |
| Net cash used in operating activities | -$128.5M | -$41.6M |
| Purchases of property and equipment | -$1.0M | -$3.2M |
| Purchases of marketable securities | -$141.6M | -$437.7M |
| Maturities of marketable securities | $259.5M | $413.1M |
| Net cash provided by (used in) investing activities | $116.8M | -$27.8M |
| Proceeds from exercise of stock options | $425.0K | $2.8M |
| Proceeds from issuance of common stock under the employee stock purchase plan | $462.0K | $574.0K |
| Net cash provided by financing activities | $887.0K | $103.0M |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -$10.8M | $33.6M |
| Purchases of property and equipment included in accounts payable and accrued expenses | $0 | $560.0K |
| Vesting of options early exercised subject to repurchase | $14.0K | $51.0K |
| Cash paid for income taxes | $1.7M | $4.6M |
| Issuance of common stock and pre-funded warrants in registered direct offering, net of issuance costs | $392.0K |
No quarter-by-quarter statement was filed.
Leadership
Who has led Entrada Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
Chief operating officer
2025
- Chief executive officerDipal Doshi Oct 28, 2021 to now10
- PresidentNathan J. Dowden Mar 5, 2024 to Oct 18, 202411
- PresidentNatarajan Sethuraman Oct 18, 2024 to now12
- PresidentDipal Doshi Oct 28, 2021 to Dec 22, 202310
- Chief financial officerKory James Wentworth Oct 28, 2021 to now13
- Chief operating officerNathan J. Dowden Oct 28, 2021 to now14
Board members and other officers (11)
- Chief Scientific OfficerNatarajan Sethuraman Oct 28, 2021 to Sep 10, 202415
- Chief Medical OfficerNerissa Kreher Oct 28, 2021 to Sep 6, 202316
- Board memberMaha Radhakrishnan Jun 3, 2025 to now17
- Board memberBernhardt G. Zeiher Apr 4, 2023 to now18
- Board memberGina Chapman Sep 5, 2023 to now19
- Board memberCarole Nuechterlein Oct 28, 2021 to Jun 6, 202220
- Board memberDipal Doshi Oct 28, 2021 to now10
- Board memberJohn F. Crowley Oct 28, 2021 to Jun 12, 202321
- Board memberKush Parmar Oct 28, 2021 to now22
- Board memberMary Thistle Oct 28, 2021 to now23
- Board memberPeter S. Kim Oct 28, 2021 to now24
Former names
- CycloPorters, Inc.Nov 10, 2016 to Nov 10, 20162
Timeline
- Oct 28, 2021New chief executive Dipal Doshi becomes CEO10
Filings
462 filings to the SEC since October 2021: 6 annual reports, 16 quarterly reports, 51 major events, 242 insider forms, 28 large holders, 119 other. The latest 20:
- Oct 14, 20268-K EDGAR
- Sep 10, 2026SCHEDULE 13D/A EDGAR
- Sep 9, 20264 EDGAR
- Sep 9, 20264 EDGAR
- Sep 3, 20264 EDGAR
- Sep 3, 20264 EDGAR
- Sep 3, 20264 EDGAR
- Sep 3, 20264 EDGAR
- Sep 3, 20264 EDGAR
- Sep 3, 20264 EDGAR
- Aug 31, 20264 EDGAR
- Aug 31, 20264 EDGAR
- Aug 26, 20264 EDGAR
- Aug 26, 20264 EDGAR
- Aug 14, 2026SCHEDULE 13G/A EDGAR
- Aug 10, 2026144/A EDGAR
- Aug 10, 20264 EDGAR
- Aug 10, 20264 EDGAR
- Aug 5, 202610-Q EDGAR
- Aug 5, 20268-K EDGAR
The 462 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last three years, summarized. The full record is on SEC EDGAR.
Insider trades and holders
Large holders
Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 28 such filings since October 2021, the latest 10:
- Sep 10, 2026SCHEDULE 13D/A
- Aug 14, 2026SCHEDULE 13G/A
- Nov 25, 2025SCHEDULE 13G
- Nov 18, 2025SCHEDULE 13D/A
- Nov 14, 2025SCHEDULE 13G/A
- Aug 14, 2025SCHEDULE 13G/A
- Aug 14, 2025SCHEDULE 13G/A
- May 14, 2025SCHEDULE 13G/A
- Feb 14, 2025SCHEDULE 13G
- Feb 14, 2025SCHEDULE 13G/A
From Forms 4 and Schedules 13D and 13G filed with the SEC.
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Baker Bros. Advisors LP | 5,072,730 | $37.3M | 0.2% | No change |
| 5AM Venture Management, LLC | 4,056,379 | $29.9M | 10.4% | No change |
| BlackRock, Inc. | 2,583,333 | $19.0M | 0.0% | +224,540 |
| Merck & Co., Inc. | 1,739,768 | $12.8M | 2.4% | New |
| Vanguard Capital Management LLC | 1,269,634 | $9.3M | 0.0% | +13,621 |
| Mpm Bioimpact LLC | 1,253,053 | $9.2M | 0.6% | New |
| TCG Crossover Management, LLC | 1,060,230 | $7.8M | 0.2% | −1,227,270 |
| Wellington Management Group Llp | 954,419 | $7.0M | 0.0% | −80,363 |
| Millennium Management LLC | 763,959 | $5.6M | 0.0% | +244,603 |
| StepStone Group LP | 761,277 | $5.6M | 0.3% | No change |
| Geode Capital Management, LLC | 717,430 | $5.3M | 0.0% | +50,083 |
| Aqr Capital Management LLC | 699,537 | $5.1M | 0.0% | +620,044 |
| Nantahala Capital Management, LLC | 601,150 | $4.4M | 0.1% | +441,818 |
| State Street Corp | 596,677 | $4.4M | 0.0% | +62,879 |
| Jpmorgan Chase & Co | 496,457 | $3.8M | 0.0% | +481,610 |
| Citadel Advisors LLC | 394,323 | $2.9M | 0.0% | +179,305 |
| Dimensional Fund Advisors LP | 376,136 | $2.8M | 0.0% | +51,665 |
| Northern Trust Corp | 309,942 | $2.3M | 0.0% | +74,950 |
| Jacobs Levy Equity Management, Inc | 303,459 | $2.2M | 0.0% | −30,455 |
| Vanguard Portfolio Management LLC | 254,130 | $1.9M | 0.0% | +33,636 |
| Charles Schwab Investment Management Inc | 197,136 | $1.5M | 0.0% | −17,615 |
| Longaeva Partners L.P. | 195,237 | $1.4M | 0.0% | −9,741 |
| Morgan Stanley | 191,650 | $1.4M | 0.0% | +15,524 |
| Renaissance Technologies LLC | 191,000 | $1.4M | 0.0% | −11,084 |
| Quantinno Capital Management LP | 188,839 | $1.4M | 0.0% | +117,821 |
13F reports cover disclosed long positions in U.S. stocks only.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10SEC EDGARDipal Doshi, Chief executive officer
- 11SEC EDGARNathan J. Dowden, President
- 12SEC EDGARNatarajan Sethuraman, President
- 13
- 14
- 15
- 16
- 17SEC EDGARMaha Radhakrishnan, Board member
- 18SEC EDGARBernhardt G. Zeiher, Board member
- 19SEC EDGARGina Chapman, Board member
- 20SEC EDGARCarole Nuechterlein, Board member
- 21SEC EDGARJohn F. Crowley, Board member
- 22SEC EDGARKush Parmar, Board member
- 23SEC EDGARMary Thistle, Board member
- 24SEC EDGARPeter S. Kim, Board member